ARTICLE | Deals
Jan. 7 Quick Takes: AZ adds another amyloidosis mAb via Neurimmune deal
Plus: a16z’s $9B in new funds earmarks cash for bio, and updates from Virtue, AN2, Ultragenx-Regeneron and more
January 8, 2022 3:17 AM UTC
For $30 million up front, AstraZeneca plc (LSE:AZN; NASDAQ:AZN) will receive exclusive, worldwide rights to NI006 from Neurimmune AG, a mAb in Phase Ib testing to treat cardiomyopathy associated with TTR-mediated amyloidosis (ATTR-CM). The Zurich-based biotech is eligible for $730 million in milestones, plus royalties. Last year, AstraZeneca acquired partner Caelum Biosciences Inc. to gain a mAb to treat light-chain (AL) amyloidosis.
Andreessen Horowitz has raised a $1.5 billion “bio” fund as part of an overall $9 billion raise that also includes $5 billion growth and $2.5 billion venture funds. The firm invests in life sciences companies at the confluence of biology and tech...